Semper Paratus Acquisition filed a registration statement outlining its proposed business combination with Tevogen Bio, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
A meeting date for the shareholder vote was not included in the S-4.
If approved as expected by the end of the year, upon closing Tevogen Bio is expected to list on the NYSE American under new ticker symbols TVGN and TVGNW.
Announced in June, the deal has a pro forma equity value of approximately $1.2 billion.
Sempter Paratus raised $345 million in a November 2021 IPO. The SPAC in May sold its sponsor equity to SSVK Associates. Read more.
